Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>NanoViricides, Inc. (NNVC) is a clinical-stage company that is developing NV-387, a novel antiviral compound that will be initiating a clinical trial against MPox in late 2025/early 2026, with multiple other potential anti-viral indications.</li><li>Preclinical results show that NV-387 possesses anti-viral activity against a wide range of pathogens, including respiratory syncytial virus (RSV), influenza, and measles.</li><li>The company will be filing a clinical trial authorization (CTA) in order to conduct a Phase 2 clinical trial for the treatment of MPox in the Democratic Republic of Congo.</li></ul>

NanoViricides, Inc. (NNVC) is a clinical-stage company that is developing NV-387, a novel antiviral compound that will be initiating a clinical trial against MPox in late 2025/early 2026, with multiple other potential anti-viral indications.Preclinical results show that NV-387 possesses anti-viral activity against a wide range of pathogens, including respiratory syncytial virus (RSV), influenza, and measles.The company will be filing a clinical trial authorization (CTA) in order to conduct a Phase 2 clinical trial for the treatment of MPox in the Democratic Republic of Congo.

NanoViricides

NNVC: Getting Set for Phase 2 Trial of